Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06385405
Other study ID # 2024y0423
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 27, 2024
Est. completion date May 2026

Study information

Verified date June 2024
Source Shanghai Mental Health Center
Contact TianHong Zhang, Doctor
Phone 13127577024
Email zhang_tianhong@126.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study will focus on the hypothesis that repetitive transcranial magnetic stimulation (TMS) based on EEG personalized modulation may be more effective in promoting symptomatic relief of major depressive disorder (MDD), and will rely on the platform of neuroimaging and function brain imaging of Shanghai Mental Health Center (SMHC), an authoritative institution in the field of mental health. We will eventually facilitate optimization of physical therapy for major depressive disorder (MDD).


Description:

Read more »
Read more »

Study Design


Intervention

Device:
Individualized alpha frequency Transcranial Magnetic Stimulation (aTMS) Treatment
The target site for alpha frequency Transcranial Magnetic Stimulation (aTMS) was identified based on alterations in alpha band spectral connectivity, which were measured using four frontal electroencephalography (EEG) channels (F1, F3, F5, FC3) subsequent to 10Hz transcranial magnetic stimulation (TMS). Alpha band spectral connectivity refers to the degree of similarity between the spectral waveforms of the alpha band across channels. The alpha frequency stimulation rate was defined as the highest spectral peak within the alpha band ranging from 7 to 13 Hz of the target channel. Each treatment cycle consisted of 20 daily sessions over a 4-week span, and stimulation was administered for 2 seconds every minute for a total duration of 20 minutes at 80% of the individual's motor threshold.
10Hz-frequency TMS treatment over the left dorsolateral prefrontal cortex (DLPFC)
Prefrontal Transcranial Magnetic Stimulation (TMS) therapy repeated daily over 4 weeks (20 sessions) is US Food and Drug Administration (FDA) approved for treating Major Depressive Disorder in adults who have not responded to prior antidepressant medications. The strongest evidence supports high-frequency treatment over the left dorsolateral prefrontal cortex (DLPFC). The common stimulation frequency is 10Hz. It is usually applied for a duration of 4 weeks, 5 days a week.

Locations

Country Name City State
China Shanghai Mental Health Center Shanghai Shanghai

Sponsors (4)

Lead Sponsor Collaborator
Shanghai Mental Health Center National Natural Science Foundation of China, Shanghai Jiao Tong University School of Medicine, Shanghai Municipal Science and Technology Commission

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary the response rate It will be determined by Hamilton Depression Scale(HAMD-24 item) score. Specifically, the response rate is defined as a 30% decrease in HAMD score from those measured at baseline. 4 weeks
Secondary complete remission rate It will be determined by Hamilton Depression Scale(HAMD-24 item) score. Specifically, the complete remission rate is defined as the HAMD score of less than 8 at the follow-up point. 4 weeks
Secondary alpha band spectral connectivity in electroencephalogram (EEG) parameters It will be determined by the changes of alpha band spectral connectivity in EEG parameters. Specifically, the EEG index is the change in alpha band spectral connectivity before and after a single TMS intervention, representing the functional connectivity between the frontal lobe and other brain regions across the entire brain. 4 weeks
Secondary Evaluation of therapeutic effect It will be determined using the criteria for the global improvement(GI) from Clinical Global Impression(CGI). Specifically, the global improvement(GI) will be rated by the clinician for the degree of improvement in the subject's current condition compared to baseline at enrollment on an 8-point scale from 0-7(the rating "1" refers to significant progress, and the rating "2" refers to progress, etc.). 4 weeks
See also
  Status Clinical Trial Phase
Completed NCT00316160 - Sexual Functioning Study With Antidepressants Phase 4
Completed NCT05416957 - Food Effect Bioavailability Study of Vortioxetine Hemihydrobromide Orally Disintegrating Tablets Phase 1
Active, not recruiting NCT03642964 - A Study in Patients With Major Depressive Disorder Phase 2
Terminated NCT01111565 - Study to Evaluate the Efficacy, Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) Phase 3
Completed NCT01912196 - Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD) Phase 2
Completed NCT00958204 - Light, Ion, and Fluoxetine Efficacy (LIFE) in Depression Phase 3
Completed NCT00102492 - Study Of GW679769 In Major Depressive Disorder Phase 2
Completed NCT02012218 - Brexpiprazole as Adjunctive Therapy With Major Depressive Disorder and an Inadequate Response to Previous Adjunctive Therapy Phase 3
Completed NCT01477203 - Multimodal Assessment of Neurobiological Markers for Psychiatric Disorders Phase 4
Completed NCT00768430 - Optimization of IV Ketamine for Treatment Resistant Depression Phase 2
Completed NCT00559299 - Patient Tolerability Study of GSK163090 Phase 1
Terminated NCT01123707 - To Assess the Safety and Tolerability of an Oral Aripiprazole/Escitalopram Combination Therapy in Participants With Major Depressive Disorder (MDD) Phase 3
Completed NCT04403373 - Effectiveness of Walking Exercise in Improving Depression in Older Adults With Major Depressive Disorder, A Pilot Study N/A
Completed NCT05541302 - Retrospective TMS Therapy for Adults With MDD
Completed NCT00330616 - Study Of Bupropion SR (323U66) In Patients With Major Depressive Disorder In Japan Phase 2
Recruiting NCT03012724 - Efficacy of H7-Coil DTMS Compared to H1-Coil DTMS in Subjects With Major Depression Disorder (MDD) N/A
Completed NCT02380066 - Comparison of Anyu Peibo With Placebo in Treatment of MDD Phase 2
Not yet recruiting NCT02395263 - Comparison of Yuxintine With Placebo in Treatment of MDD Phase 2
Completed NCT01187407 - A Study of Flexible or Fixed Dose LY2216684 as Adjunctive Treatment for Participants With Major Depressive Disorder Who Have Had a Partial Response to Selective Serotonin Reuptake Inhibitor (SSRI) Treatment Phase 3
Completed NCT00448292 - A Efficacy Study of PRX-00023 in Patients With Major Depressive Disorder Phase 2